Myosin is a site of action of okadaic acid that is known as a phosphatase inhibitor
K, Hayakawa, K, Kohama
openaire +2 more sources
Myosin Inhibitors Can Reduce Primary Mitral Regurgitation by Improving Systolic Anterior Motion of the Mitral Leaflets. [PDF]
Roehl K, Alsidawi S.
europepmc +1 more source
Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with <i>RAF1</i>-associated Noonan syndrome-case report. [PDF]
Seghers HM +4 more
europepmc +1 more source
Regulation of platelet contractility by agonists present across a thrombus. [PDF]
Hiebner DW +9 more
europepmc +1 more source
Pharmacologic therapies for hypertrophic cardiomyopathy: The past, the present, and the future. [PDF]
Halațiu VB, Cozac DA, Scridon A.
europepmc +1 more source
The Dawn of a New Era in Hypertrophic Cardiomyopathy. [PDF]
Yu WC.
europepmc +1 more source
Mavacamten in Obstructive Hypertrophic Cardiomyopathy and C282Y Homozygous Hereditary Hemochromatosis: A First-in-Human Report. [PDF]
Sam R +4 more
europepmc +1 more source
Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography. [PDF]
Polizzi R +5 more
europepmc +1 more source
<i>RET</i> fusion partners dictate oncogenic potential in undifferentiated spindle cell sarcomas. [PDF]
Gui Q +12 more
europepmc +1 more source
Non-muscle tropomyosins inhibit myosin-19 and dynamically localize to mitochondrially associated actin filaments. [PDF]
Thompson CP +4 more
europepmc +1 more source

